Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863941 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00863941: Completed Phase 1 study, sponsored by Actavis.
NCT00863941 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00863941, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.
Interventions
- DRUG Abrika Bupropion 150 mg XL Tablet, single dose
- DRUG Wellbutrin XL® 150 mg Tablet, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-06 |
| Est. Completion | 2004-07 |
| Phase | Phase 1 |
What the finished NCT00863941 record still lists
NCT00863941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Abrika Bupropion 150 mg XL Tablet, single dose is the first listed.
NCT00863941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00863941 about?
NCT00863941 is a clinical study titled "A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions". To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.
What is the current status of trial NCT00863941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2004-06. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00863941?
The interventions under investigation include: Abrika Bupropion 150 mg XL Tablet, single dose (DRUG), Wellbutrin XL® 150 mg Tablet, single dose (DRUG).
Who is sponsoring clinical trial NCT00863941?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00863941's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia